目的 研究前列癃閉通片聯(lián)合愛普列特治療良性前列腺增生癥的臨床療效。方法 選擇2023年2月—2024年6月蘇州大學附屬第四醫(yī)院收治的良性前列腺增生癥患者152例，隨機分為對照組（74例）和治療組（78例）。對照組口服愛普列特片，5 mg/次，2次/d。治療組在對照組基礎上口服前列癃閉通片，3片/次，3次/d。兩組患者連續(xù)治療4個月。觀察兩組患者臨床療效，比較治療前后兩組患者國際前列腺癥狀評分（IPSS）評分，最大尿流率和減少殘余尿量，血清性激素睪酮（T）和雌二醇（E₂）水平，及血清炎癥因子C反應蛋白（CRP）、白細胞介素-6（IL-6）和腫瘤壞死因子α（TNF-α）水平。結果 治療后，治療組臨床總有效率明顯高于對照組（97.43% vs 83.78%，P＜0.05）。治療后，與治療前相比，兩組IPSS評分明顯下降（P＜0.05），且治療組患者IPSS評分明顯低于對照組（P＜0.05）。治療后，兩組的最大尿流率均顯著提高，殘余尿量顯著減少（P＜0.05），且治療組尿動力學參數(shù)明顯優(yōu)于對照組（P＜0.05）。治療后，兩組T水平明顯升高，而E₂水平明顯下降（P＜0.05），且治療組性激素水平明顯好于對照組（P＜0.05）。治療后，兩組血清CRP、IL-6、TNF-α水平與治療前相比明顯下降，且治療組上述3種炎癥因子水平和對照組相比明顯降低（P＜0.05）。結論 前列癃閉通片聯(lián)合愛普列特治療良性前列腺增生癥具有良好的臨床療效，能有效改善性激素水平、尿動力學指標和血清炎癥因子，且治療效果優(yōu)于單一藥物治療。

Objective To study the clinical efficacy of Qianlielong Bitong Tablets combined with aipulite in treatment of benign prostatic hyperplasia. Methods Patients (152 cases) with benign prostatic hyperplasia in the Fourth Affiliated Hospital of Soochow University from February 2023 to June 2024 were randomly divided into control (74 cases) and treatment (78 cases) group. Patient in the control group were po administered with Epristeride Tablets, 5 mg/time, twice daily. Patient in the treatment group were po administered with Qianlielong Bitong Tablets on the basis of the control group, 3 tablets/time, three times daily. Patient in two groups were treated for 4 months. After treatment, the clinical evaluations were evaluated, and the IPSS scores, the maximum urinary flow rate and residual urine volume in bladder, sex hormone T and E₂ levels, and serum factors CRP, IL-6, TNF-α levels in two groups before and after treatment were compared. Results After treatment, the clinical effective rate in the treatment group was significantly higher than that in the control group (97.43% vs 83.78%, P < 0.05). After treatment, compared with before treatment, the IPSS scores in two groups were decreased significantly (P < 0.05), and the IPSS scores in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the maximum urinary flow rate in two groups was significantly increased, residual urine volume was significantly reduced (P < 0.05), and the urodynamic parameters of the treatment group were significantly better than those of the control group (P < 0.05). After treatment, T levels were significantly increased in two groups, but E₂ levels were significantly decreased (P < 0.05), and sex hormone levels in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the levels of serum CRP, IL-6, and TNF-α in two groups were decreased significantly compared with before treatment, and the levels of the above three inflammatory factors in the treatment group were significantly decreased compared with the control group (P < 0.05). Conclusion The combined treatment of Qianlielong Bitong Tablets and epristeride for benign prostatic hyperplasia demonstrates has good clinical efficacy. It effectively improves sex hormone levels, urodynamic parameters, and serum inflammatory factors, and the treatment effect is superior to monotherapy.

R983

江蘇省衛(wèi)生健康委科研課題（ZD2023042）